The Underlying Biology

Premium

As a physician, Giuseppe Bianchi at San Raffaele Hospital in Milan finds it frustrating that he can only determine which antihypertensive drug will work in a given patient with a trial-and-error approach. Most of the available drugs only work in about 30 to 40 percent of the patient population, and those that do work affect the disease physiology, not the underlying molecular mechanisms. Bianchi, however, hopes to combine an understanding of the biological basis of the disease with genetic tools to find what drug works best in a particular patient.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.